Live Breaking News & Updates on Recurrence Free Survival
Stay updated with breaking news from Recurrence free survival. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EORTC and Pierre Fabre launch phase 3 trial for melanoma pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress May 12, 2021 on track for Phase III European trial in stage IIIB/C melanoma. Opening of additional clinical centers to boost recruitment rate is ongoing. E Fibromun Philogen is well capitalized, about th the here (https://us06web.zoom.us/webinar/register/WN nEuoFxsHTXSTdtS4RBslYg) Siena (Italy), 12 May 2021 - (Globe Newswire) - Philogen S.p.A. (BIT:PHIL) - a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ligands, is pleased to announce progress updates for its fully-owned immunocytokine and small molecule programs. ....
Philogen Announces the Completion of a Second Interim Analysis of Its Phase III Clinical Program With Nidlegy for the Treatment of Melanoma Nidlegy was found to be well-tolerated and 149 out of the anticipated 214 patients have been safely treated. Data Safety Monitoring Board recommends to continue the study as planned. News provided by Share this article Share this article SIENA, Italy, Jan. 13, 2021 /PRNewswire/ Philogen S.p.A., a clinical-stage biotechnology company focused on antibody-based therapeutics, is pleased to announce that 50% of the expected events for the primary outcome analysis of the PIVOTAL study were reached in December 2020. In this phase III clinical trial, the effect of Nidlegy™ is evaluated in melanoma patients with locally advanced, fully resectable metastatic cancer, and at the time of the second interim analysis, had already recruited 149 out of the anticipated 214 patients (one additional patient was enrolled recently). As a co ....